Physician

Brian K. Adler, M.D.

According to 2025 Medicare claims, Brian Adler, M.D. (NPI: 1588774624) practices hematology/oncology in the Birmingham, AL market, with the plurality of this provider's patient population coming from Jefferson, AL. This provider's primary affiliated billing organization is BIRMINGHAM HEMATOLOGY ONCOLOGY ASSOC LLC (NPI: 1841216389; TIN: 522170293) and primary practice location at 35209-6889.

Adler's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 257 traditional Medicare patients, billed 73,985 HCPCS/CPT codes, and received $1,522,859 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 2,374 prescription claims across 255 beneficiaries totaling $3,095,524 in drug costs, led by Revlimid (Lenalidomide). DME data shows 161 claims. Open Payments data shows 155 records totaling $3,336. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $1,439,301 to $3,095,524. In contrast, DME billing represents a smaller volume and declined steadily, from $4,018 to $2,319.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	381	74,917	$942,476
2016	449	115,323	$1,399,728
2017	344	96,867	$1,482,848
2018	330	79,552	$1,453,330
2019	352	89,921	$1,600,778
2020	285	55,918	$1,468,964
2021	295	61,139	$1,186,494
2022	274	86,773	$1,416,050
2023	262	80,186	$1,169,629
2024	257	73,985	$1,522,859

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	189	1,913	$1,439,301
2016	200	1,831	$1,913,909
2017	207	2,109	$1,963,825
2018	222	2,154	$2,189,324
2019	213	2,279	$3,466,868
2020	216	2,514	$3,586,933
2021	236	2,428	$3,249,209
2022	266	2,573	$3,600,616
2023	246	2,330	$3,166,784
2024	255	2,374	$3,095,524

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	215	$131,241
2016	N/R	192	$130,128
2017	N/R	93	$87,468
2018	N/R	201	$138,989
2019	N/R	173	$141,049
2020	N/R	157	$92,036
2021	N/R	179	$179,952
2022	N/R	178	$158,259
2023	N/R	201	$160,363
2024	N/R	161	$184,341

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	57	65	$126
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	140	330	$83
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	104	140	$12
36415	Insertion of needle into vein for collection of blood sample	187	586	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	182	679	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	40	1,120	$733,779
Lenalidomide	Lenalidomide	57	1,596	$689,432
Tagrisso	Osimertinib Mesylate	22	660	$373,474
Jakafi	Ruxolitinib Phosphate	20	600	$337,266
Cabometyx	Cabozantinib S-Malate	11	330	$268,487

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	12	$49,019
J1575	Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin	N	N/R	11	$44,538
J1558	Injection, immune globulin (xembify), 100 mg	N	N/R	12	$42,746
J1576	Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	13	$40,962
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	13	$4,285

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	155	$3,336	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Brian K. Adler, M.D.?

Tedicare shows public-source Medicare data for Brian K. Adler, M.D. (NPI 1588774624), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Brian K. Adler, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Brian K. Adler, M.D.?

Brian K. Adler, M.D. is linked to BIRMINGHAM HEMATOLOGY ONCOLOGY ASSOC LLC (billing NPI 1841216389) in the available physician profile data.

Does Brian K. Adler, M.D. have Open Payments data?

Brian K. Adler, M.D. has 155 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.